CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Tryptamine Therapeutics Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Tryptamine Therapeutics Ltd
C/o Bio101 Financial Advisory Pty Ltd
Suite 201, 697 Burke Road, Camberwell
Phone: +61 384190827p:+61 384190827 MELBOURNE, VIC  3124  Australia Ticker: TYPTYP
Business Summary
Tryptamine Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on the development of an advanced and scalable intravenous-infused psilocin formulation, which can be used in conjunction with psychotherapy to address significant unmet medical needs. It is focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. It intends to accomplish this through the development of an IV infusion of psilocin (the active metabolite of psilocybin). Its lead programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. The Company is engaged in pursuing Phase II clinical trials using its psilocybin and psilocin-based drug products for chronic pain and eating disorders. The Company's pipeline products include TRP-8803 and TRP-8802.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20246/30/2024Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board MarkDavies 6/22/2023 6/22/2023
Chief Executive Officer, Director JasonCarroll 4/11/2024 10/1/2023
Chief Financial Officer HamishGeorge 9/1/2024 9/1/2024
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Tryp Therapeutics Inc 301 - 1665 Ellis Street KELOWNA BC Canada

Business Names
Business Name
EX1
EX1DA
Tryp Therapeutics Inc
TYP

General Information
Outstanding Shares: 1,138,921,585 (As of 6/30/2024)
Shareholders: 2,169
Stock Exchange: ASX


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025